AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29313577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risorine (Rifampicin 200 mg + Isoniazid 300 mg + Piperine 10 mg)
Number of subjects: 216
Study 29313577 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-TB therapy
Number of subjects: 216
Study 25450635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (one subcutaneous injection/week for 4 weeks) in addition to standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Number of subjects: 30
Study 25450635 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Number of subjects: 30
Study 22921686 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized counseling about contraceptive options and screening for contraindications
Number of subjects: 814
Study 22921686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computerized counseling)
Number of subjects: 814
Study 22921686 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized counseling
Number of subjects: 814
Study 21688900 — intervention group
Group type: EXPERIMENTAL
Intervention: $1,000 increase in annual family income
Number of subjects: 0
Study 18239394 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks (50 Joules)
Number of subjects: 95
Study 16869919 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific, constructive feedback on knot-tying skill
Number of subjects: 33
Study 16869919 — intervention group
Group type: COMPARATOR
Intervention: General compliments
Number of subjects: 33
Study 12923649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing partially hydrogenated fat (5.6% of energy)
Number of subjects: 10
Study 12923649 — intervention group
Group type: COMPARATOR
Intervention: Diet high in palmitic acid (10.6% of energy)
Number of subjects: 10
Study 11203827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric (composite, Group A: n = 36)
Number of subjects: 37
Study 11203827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (compomer, Group B: n = 79)
Number of subjects: 37
Study 11203827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (resin-modified glass ionomer cement, Group C: n = 51)
Number of subjects: 37
Study 11203827 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac-Fil (resin-modified glass ionomer cement, Group D: n = 31)
Number of subjects: 37
Study 9310601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 119
Study 9310601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (good-quality studies)
Number of subjects: 119
Study 9310601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (corrected for publication bias)
Number of subjects: 119
Study 9310601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (single remedy for seasonal allergies)
Number of subjects: 119
Study 9310601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy (postoperative ileus)
Number of subjects: 119
Study 7508742 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine tablet (150 micrograms)
Number of subjects: 14
Study 7508742 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine solution (150 micrograms)
Number of subjects: 14
Study 3712166 — intervention group
Group type: EXPERIMENTAL
Intervention: High medium-chain triglyceride (MCT) formula
Number of subjects: 15
Study 3712166 — intervention group
Group type: COMPARATOR
Intervention: Low medium-chain triglyceride (MCT) formula
Number of subjects: 15
Study 3712166 — intervention group
Group type: EXPERIMENTAL
Intervention: High MCT formula
Number of subjects: 15
Study 3712166 — intervention group
Group type: COMPARATOR
Intervention: Low MCT formula
Number of subjects: 15
Study 30167644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 33
Study 30167644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30167644 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 26259519 — intervention group
Group type: EXPERIMENTAL
Intervention: GS‐4997 (apoptosis signal‐regulating kinase 1 inhibitor)
Number of subjects: 0
Study 26259519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23514876 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ROM isolated lumbar extension exercise
Number of subjects: 24
Study 23514876 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited ROM isolated lumbar extension exercise
Number of subjects: 24
Study 23514876 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 21931019 — intervention group
Group type: EXPERIMENTAL
Intervention: TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks
Number of subjects: 201
Study 21931019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21931019 — intervention group
Group type: EXPERIMENTAL
Intervention: TASQ
Number of subjects: 201
Study 18248654 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg intravenous bolus infusion for 30 min followed by esomeprazole 8 mg/h intravenously for 71.5 h
Number of subjects: 2008
Study 18248654 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 72 h
Number of subjects: 2008
Study 18248654 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg intravenous bolus infusion followed by esomeprazole 8 mg/h intravenously
Number of subjects: 2008
Study 16449416 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT) plus pill‐placebo
Number of subjects: 280
Study 16449416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) plus citalopram (20 to 40 mg per day)
Number of subjects: 280
Study 16449416 — intervention group
Group type: COMPARATOR
Intervention: Standardized clinical management (CM) plus pill‐placebo
Number of subjects: 280
Study 16449416 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized clinical management (CM) plus citalopram (20 to 40 mg per day)
Number of subjects: 280
Study 12729356 — intervention group
Group type: EXPERIMENTAL
Intervention: Merlano chemo-radiotherapy
Number of subjects: 48
Study 10589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (dextran 70 or gelafundin 35,000)
Number of subjects: 50
Study 10589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 50
Study 10589889 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids (Ringer's lactate or 0.9%-weight/volume saline)
Number of subjects: 50
Study 8739093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 3 g/day
Number of subjects: 36
Study 8739093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8739093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 1.5 g/day
Number of subjects: 36
Study 8739093 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1.5 g/day
Number of subjects: 36
Study 1953218 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized impedance plethysmography (CIP)
Number of subjects: 246
Study 1953218 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized impedance plethysmography (CIP) for proximal DVT
Number of subjects: 246
Study 7008184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.44 g acetylsalicylic acid (ASA)
Number of subjects: 25
Study 7008184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.96 g acetylsalicylic acid (ASA)
Number of subjects: 25
Study 30550301 — intervention group
Group type: EXPERIMENTAL
Intervention: EC (intervention condition)
Number of subjects: 1686
Study 30550301 — intervention group
Group type: COMPARATOR
Intervention: CC (control condition)
Number of subjects: 1686
Study 27692566 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Kissing Balloon Technique (FKBT)
Number of subjects: 108
Study 27692566 — intervention group
Group type: COMPARATOR
Intervention: Single-stent implantation without FKBT
Number of subjects: 108
Study 26341393 — intervention group
Group type: EXPERIMENTAL
Intervention: AVD+ (audio and visual distraction)
Number of subjects: 0
Study 26341393 — intervention group
Group type: COMPARATOR
Intervention: AVD- (non-distraction)
Number of subjects: 0
Study 25675559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with anti-hypertensive plaster
Number of subjects: 60
Study 25675559 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 60
Study 22409641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 84
Study 22409641 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 84
Study 22409641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 19450370 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) supplementation (45 microg for 8 weeks)
Number of subjects: 55
Study 19450370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17596256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 100
Study 17596256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 100
Study 17596256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 100
Study 10812288 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (T)
Number of subjects: 45
Study 10812288 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (C)
Number of subjects: 45
Study 9092959 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 12
Study 8251778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6‐benzo‐alpha‐pyrone (200 mg tablets, two daily)
Number of subjects: 104
Study 8251778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets daily)
Number of subjects: 104
Study 2870876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg loprazolam
Number of subjects: 89
Study 2870876 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg loprazolam
Number of subjects: 89
Study 2870876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 31757794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 12 weeks
Number of subjects: 0
Study 31757794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0
Study 31757794 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment of cultured human adipocytes
Number of subjects: 0
Study 31757794 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 29733520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango consumption (300 g for 4 weeks)
Number of subjects: 0
Study 29733520 — intervention group
Group type: COMPARATOR
Intervention: Equivalent amount of fiber
Number of subjects: 0
Study 28236989 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24161369 — intervention group
Group type: COMPARATOR
Intervention: Thin liquid barium (THIN)
Number of subjects: 100
Study 24161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid barium thickened with a starch‐based agent (STARCH)
Number of subjects: 100
Study 24161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid barium thickened with a gum‐based agent (GUM)
Number of subjects: 100
Study 22055271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 6x10^9
Number of subjects: 47
Study 22055271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 40
Study 19965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 40
Study 18190615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet, placebo fibre supplement, and loperamide
Number of subjects: 63
Study 18190615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplement, neutral diet, and loperamide
Number of subjects: 63
Study 15864137 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol treatment
Number of subjects: 206
Study 15864137 — intervention group
Group type: COMPARATOR
Intervention: Family history of psoriasis
Number of subjects: 206
Study 12645717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined system (heparin-coated, centrifugal pump, closed circuit)
Number of subjects: 40
Study 12645717 — intervention group
Group type: COMPARATOR
Intervention: Conventional system (uncoated system, roller pump, hard shell venous reservoir)
Number of subjects: 40
Study 10641539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation psychotherapy (including pathogenetic and symptomatic psychotherapy)
Number of subjects: 0
Study 10641539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation psychotherapy
Number of subjects: 0
Study 8787184 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere damage (RH-damaged group)
Number of subjects: 28
Study 8787184 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere damage (LH-damaged group)
Number of subjects: 28
Study 8787184 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28
Study 1804598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g twice a day i.v.
Number of subjects: 72
Study 1804598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily i.v.
Number of subjects: 72
Study 30057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Swedish massage and preferred music
Number of subjects: 240
Study 30057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage
Number of subjects: 240
Study 30057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 240
Study 30057058 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 26650825 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (abdominal massage, abdominal muscle stretching, education on proper defecation position)
Number of subjects: 30
Study 26650825 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 30
Study 26650825 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received the program before the second chemotherapy cycle)
Number of subjects: 30
Study 24392491 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG) as a barrier
Number of subjects: 20
Study 24392491 — intervention group
Group type: COMPARATOR
Intervention: Bioresorbable collagen membrane (control)
Number of subjects: 20
Study 23146636 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 25
Study 23146636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23146636 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe pain during injection
Number of subjects: 25
Study 20491987 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment (n = 43)
Number of subjects: 89
Study 20491987 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal treatment (n = 46)
Number of subjects: 89
Study 19253522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (80% of patients)
Number of subjects: 145
Study 19253522 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker monotherapy
Number of subjects: 145
Study 19253522 — intervention group
Group type: COMPARATOR
Intervention: Diuretic monotherapy
Number of subjects: 145
Study 19253522 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (20% of patients)
Number of subjects: 145
Study 16012079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg of racemic rabeprazole
Number of subjects: 16
Study 16012079 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of racemic lansoprazole
Number of subjects: 16
Study 12945829 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/d)
Number of subjects: 28
Study 12945829 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBCr (3 g/d HMB, 3 g/d Cr)
Number of subjects: 28
Study 12945829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 11012004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile moisturizer and sterile cleanser used in combination, applied once or twice daily for 28 days
Number of subjects: 98
Study 8711553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.4 g/kg/day for 5 days)
Number of subjects: 42
Study 8711553 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar volume daily for 5 days)
Number of subjects: 42
Study 8711553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 42
Study 8711553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2005562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound anterior capsule cleaning
Number of subjects: 62
Study 2005562 — intervention group
Group type: COMPARATOR
Intervention: Intercapsular procedure without ultrasound cleaning
Number of subjects: 62
Study 6195236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-detergent
Number of subjects: 5536
Study 6195236 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated soap
Number of subjects: 5536
Study 31352063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31
Study 31352063 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 31
Study 31352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 31
Study 28067075 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic aortobifemoral bypass (LABF)
Number of subjects: 30
Study 28067075 — intervention group
Group type: COMPARATOR
Intervention: Open aortobifemoral bypass (OABF)
Number of subjects: 30
Study 26462611 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow chewing (50 chews min‐1)
Number of subjects: 14
Study 26462611 — intervention group
Group type: COMPARATOR
Intervention: Fast chewing (100 chews min‐1)
Number of subjects: 14
Study 24464632 — intervention group
Group type: EXPERIMENTAL
Intervention: Combivir® (zidovudine [ZDV] + lamivudine [3TC]) + Aluvia® (lopinavir/ritonavir [LPV/RTV])
Number of subjects: 30
Study 22011265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 40 mg/kg/24 h
Number of subjects: 252
Study 22011265 — intervention group
Group type: COMPARATOR
Intervention: First-generation cephalosporin 150 mg/kg/24 h
Number of subjects: 252
Study 22011265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 252
Study 22011265 — intervention group
Group type: COMPARATOR
Intervention: First-generation cephalosporin
Number of subjects: 252
Study 22011265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and first-generation cephalosporin
Number of subjects: 252
Study 19545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to optimise secondary prevention of coronary heart disease
Number of subjects: 903
Study 19545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy involving telephoning practices, posting information, visiting practices, identifying potential participants, posting invitations and obtaining consent
Number of subjects: 903
Study 19545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative relationship between researcher and practice staff
Number of subjects: 903
Study 19545366 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring progress within trials and tailoring strategies
Number of subjects: 903
Study 17469676 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel study design (randomized start or withdrawal)
Number of subjects: 0
Study 17469676 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers
Number of subjects: 0
Study 16089138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng quxie granule (FQG) + conventional western medicine (WM)
Number of subjects: 59
Study 16089138 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine (WM) alone
Number of subjects: 59
Study 16089138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng quxie granule (FQG) alone
Number of subjects: 59
Study 12029409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 138
Study 12029409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 138
Study 12029409 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study 10206604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with no body weight support
Number of subjects: 18
Study 10206604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with 15% body weight relief
Number of subjects: 18
Study 10206604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with 30% body weight relief
Number of subjects: 18
Study 10206604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking (all conditions)
Number of subjects: 18
Study 10206604 — intervention group
Group type: COMPARATOR
Intervention: Floor walking
Number of subjects: 18
Study 7843696 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 weeks of natural IFN‐alpha treatment
Number of subjects: 88
Study 7843696 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 weeks of natural IFN‐alpha treatment
Number of subjects: 88
Study 2146903 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml/kg compound sodium lactate solution
Number of subjects: 75
Study 2146903 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml/kg compound sodium lactate solution + 1 g/kg dextrose
Number of subjects: 75
Study 83088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% erythromycin base in hydroalcoholic solution + 0.05% tretinoin solution
Number of subjects: 0
Study 83088 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin solution
Number of subjects: 0
Study 83088 — intervention group
Group type: COMPARATOR
Intervention: 2% erythromycin base in hydroalcoholic solution
Number of subjects: 0